Comment on "Proteomic markers associated with blood pressure, hypertension, and treatment-resistant hypertension".

Save

Dear Editor,

Dieden et al. [1], reported that circulating interleukin-1 receptor type 2 and chitinase-3-like protein 1 are linked to blood pressure and hypertension in a population-derived cohort. Linking a range of cardiovascular proteins to several hypertension types in one cohort is a good step. However, some details about how measurements were taken and how they are understood deserve comment.

Blood pressure was measured twice during one visit, while the participant lay down after resting for 10 min. Blood pressure readings taken while lying down are usually lower than those taken while sitting, and the 140/90 mmHg cutoff is based on seated measurements [2]. One visit is not sufficient to diagnose hypertension in people who have not started treatment [3].

Approximately 521 of 1188 people who were labeled as hypertensive had not started treatment; therefore, many in the case group relied on one lying-down measurement. Using a single visit can dilute the real link between proteins and blood pressure and it makes borderline results harder to understand.

NT-proBNP was measured in the lab. It is missing from any analysis. NT-proBNP is one of the proteins that has shown a link to systolic blood pressure and hypertension in earlier studies [4].

It could act as a control in this work. If NT-proBNP behaved as expected readers would feel more confident about the null results for other proteins. NT-proBNP also matters because heart strain increases both peptides and inflammatory markers so it could confound the results.

The authors point out that interleukin-1 receptor type 2 and aminopeptidase N're strongly related (rho 0.71) and it is hard to know which one is responsible for the link to systolic blood pressure. We can test this directly by putting both proteins into the statistical model. Aminopeptidase N was not linked to diastolic blood pressure, hypertension, or treatment resistance.

Interleukin-1 receptor type 2 was. This suggests that the two signals are not the same.

The mechanistic story goes in two directions. Interleukin-1 receptor type 2 is a decoy receptor that lessens interleukin-1β signalling. The discussion says that the link between interleukin-1 receptor type 2 and blood pressure is a sign of severity not a cause, which matches the Mendelian randomization evidence.

The same part then argues that the rise of interleukin-1 receptor type 2 with aminopeptidase N supports the idea that an interleukin-1 pathway is active in blood pressure control. More decoy receptors would normally mean signalling. Because interleukin-1β or its activity was not measured, we cannot tell which way the pathway is moving from these data.

The conclusions call the participants adults who do not have established cardiovascular disease. Only heart attacks and strokes were excluded. Heart failure, atrial fibrillation, and chronic kidney disease were still in the sample.

All of these conditions raise markers and change blood pressure.

Women comprised 30.5% of the cohort. This study did not provide sex-specific estimates or interaction tests, even though inflammatory profiles and hypertension types differ by sex. An area under the curve of 0.533 for the protein tells us almost nothing about whether it adds value beyond age, body mass index, and kidney function.

Checking discrimination would tell us if calling these proteins new biomarkers is fair.

CRediT authorship contribution statement

Shantanu Shivaji Gondkar: Writing – review & editing, Writing – original draft, Visualization. Suresh Kanna Subramaniam: Writing – original draft, Writing – review & editing, Visualization. Arvindraj Ravichandran: Conceptualization, Data curation, Formal analysis.

Informed consent

Not applicable.

Ethical approval

Not applicable (Commentary on a previously published article).

Declaration of Generative AI and AI-assisted technologies in the writing process

The authors used Claude (Anthropic) to draft and edit the text. The authors reviewed and edited the content and take full responsibility for it.

Funding

The authors have nothing to report.

Declaration of competing interest

The authors declare no conflicts of interest.

Related articles

PubMed

Prescribing, Medication Adherence, and Blood Pressure Goal Achievement Among Middle-to-Older Age Adults in a Primary Care Setting.

Background Blood pressure (BP) control among hypertensive people remains inadequate. This study aims to assess BP goal achievement among people prescribed antihypertensives, to examine medication nonadherence, and to identify demographics associated with goal achievements and medication nonadherence in this population. Methods This was a cross‐sectional analysis of the Mitchelstown Cohort Study Rescreen data. Goal achievement was assessed in accordance with the 2013 European guidelines, the g...

PLOS

Effectiveness of nurse-led hypertension interventions on retention, adherence, and blood pressure control among adults in low- and middle-income countries: A systematic review

Background: Hypertension affects more than 1.28 billion adults globally and remains the leading modifiable risk factor for cardiovascular disease, stroke, renal failure, and premature death. This burden is inconsistently distributed across Low- and Middle-Income Countries (LMICs), where nearly three-quarters of adults live with hypertension. This gap is largely driven by poor adherence and low retention. This systematic review aims to assess the effectiveness of nurse-led interventions on retent...